

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Golden Meditech Company Limited**  
**金衛醫療科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 8180)**

**PROFIT WARNING**

This announcement is made pursuant to rule 17.10 of the GEM Listing Rules.

The Board wishes to inform the Shareholders and potential investors that the results of the Group for the year ended 31 March 2009 may be affected by the non-cash impairment provisions incurred in our associate as the result of the fair value change in the intangible assets of the associate and the fall in exchange rate of the British Pound against Hong Kong dollars last year.

**Shareholders and potential investors are advised to exercise caution in dealing in the shares of the Company.**

This announcement is made by Golden Meditech Company Limited (the “Company”) pursuant to rule 17.10 of the Rules Governing the Listing of Securities on the Growth Enterprise Market (the “GEM”) of The Stock Exchange of Hong Kong Limited (the “GEM Listing Rules”).

The board of directors (the “Board”) of the Company wishes to inform the shareholders of the Company (the “Shareholders”) and potential investors that the results of the Company and its subsidiaries (collectively, the “Group”) for the year ended 31 March 2009 may be affected by the non-cash impairment provisions incurred in our associate. The provisions are attributable to the following two factors:

- (1) associate’s intangible assets — estimated provisions on fair value change in the associate’s intangible assets such as medical formulae and the goodwill arising from consolidation may adversely affect the results of the associate.

- (2) Fall in exchange rate of the British Pound against Hong Kong dollars — the decline of the British Pound against Hong Kong dollars will lead to foreign exchange translation losses on the Group’s interest in an associate which is denominated in the British Pound.

Although the above factors may adversely affect the performance of the Group, they do not have any immediate impact on the cashflow of the Company. The core business of the Group in the medical and healthcare industries remained sound and healthy during the year ended 31 March 2009.

The Company is still in the process of finalising the annual results of the Group for the year ended 31 March 2009. The information contained in this announcement is only based on the preliminary assessment by the Board on the information available, which has not been reviewed nor audited by the Company’s auditors. The final results of the Group for the year ended 31 March 2009 together with other information will be disclosed in the Company’s upcoming results announcement and annual report.

**Shareholders and potential investors are advised to exercise caution in dealing in the shares of the Company.**

By Order of the Board  
**Golden Meditech Company Limited**  
**Kam Yuen**  
*Chairman*

Hong Kong, 24 April 2009

*As at the date of this announcement, the Board is comprised of 7 directors. The executive directors are Kam Yuen (Chairman), Jin Lu, Lu Tian Long and Zheng Ting and the independent non-executive directors are Cao Gang, Gao Zhong Ze and Gu Qiao.*

*This announcement, for which the directors of the Company collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules and the Main Board Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (i) the information contained in this announcement is accurate and complete in all material respects and not misleading; (ii) there are no other matters the omission of which would make any statement in this announcement misleading; (iii) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.*

*This announcement will remain on the Stock Exchange websites at <http://www.hkgem.com> on the “Latest Company Announcements” page and at <http://www.hkex.com.hk> on the “Latest Listed Company Information” page for at least 7 days from the date of its publication and on the website of the Company at [www.goldenmeditech.com](http://www.goldenmeditech.com).*